Role of virus-directed therapy in soft tissue sarcoma Review
| Authors: | Chaudhary, H.; D’Angelo, S. |
| Review Title: | Role of virus-directed therapy in soft tissue sarcoma |
| Abstract: | Bone and soft tissue sarcoma are rare cancers of mesenchymal origin with the characteristics of heterogeneity and diversity that account for less than 1% of solid malignant cancers. Conventional chemotherapy remains standard of care with response rates of 10–15% that are usually dependent on histologic subtype as some subtypes are chemotherapy resistant. There remains a large unmet clinical need for new and novel options promoting the development of promising therapeutic options such as immunotherapy. With more than 80 different subtypes, the heterogeneity of sarcoma requires thoughtful clinical trial design. In the sarcoma field, recent breakthroughs have occurred in the context of histology-specific approach based on underlying tumor biology. To that end, immunotherapy approaches will need to take a similar approach. Oncolytic viruses (OVs) have emerged as a promising treatment for many solid tumors and shown encouraging results in sarcoma. This review mainly focuses on collective clinical data highlighting the role of OVs as immunotherapy being used in soft tissue sarcoma (STS) and bone sarcomas. Combining OVs with T cell-activating checkpoint inhibition, adoptive cell therapy or targeted therapies may yield increased potency, improve antitumor efficacy of oncolytic virotherapy, and offer a new prospect for the treatment of sarcoma. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | sarcoma; immunotherapy; biomarker; adenovirus; oncolytic viral therapy; tumor-infiltrating lymphocyte; t-vec |
| Journal Title: | Current Treatment Options in Oncology |
| Volume: | 23 |
| Issue: | 3 |
| ISSN: | 1527-2729 |
| Publisher: | Springer |
| Date Published: | 2022-03-01 |
| Start Page: | 404 |
| End Page: | 414 |
| Language: | English |
| DOI: | 10.1007/s11864-022-00956-2 |
| PUBMED: | 35258792 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 April 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work